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This paper looks at the environmental role of vitamin D and solar radiation as risk reduction factors in autoimmune disease.
Five diseases are considered: multiple sclerosis, type 1 diabetes, rheumatoid arthritis, autoimmune disease of the thyroid, and
inﬂammatory bowel disease. Clinical relevant studies and factors that may indicate evidence that autoimmune disease is a vitamin
D-sensitive disease are presented. Studies that have resulted in prevention or amelioration of some autoimmune disease are
discussed. An example of the utility of supplementing vitamin D in an unusual autoimmune disease, idiopathic thrombocytic
purpura, is presented.
1.Introduction
After cardiovascular disease and cancer, autoimmune dis-
eases,takenasagroup,arethethirdleadingcauseofmorbid-
ity and mortality in the industrialized world [1]. There are
more than eighty deﬁned autoimmune diseases [2] known
in humans. A multifactorial interaction between genetic pre-
disposition, immunologic, hormonal and environmental
stimuli contributes to the development of autoimmune dis-
ease[3].Agentsthatmaytriggerautoimmunediseaseinclude
infections, vaccine immunogens, adjuvants used to increase
immune response, smoking and stress, and so forth as
outlined in the literature [4]. (See Table 1). The prevalence
of some autoimmune diseases may be as high as 5% in
the general population [5]. Little is known about mitigating
factorsuntilrecently.Evidencethatautoimmunediseasemay
be a vitamin D-sensitive disease comes from many studies.
Solar radiation (UVR) and vitamin D have been shown to
inhibit the induction of a number of autoimmune diseases
in animal models [6–8]. (See Table 2). Autoimmune disease
should vary by season, temperature, level of ultraviolet
irradiance, latitude, race or skin color, BMI, physical activity,
and vitamin D supplementation, if it is a vitamin D-sensitive
process.
This paper will discuss the interaction between the host,
the agent, and the environment as depicted in Figure 1.
The environmental factor being considered is UVB radiation
induced vitamin D or supplemental vitamin D. Five autoim-
mune diseases will be discussed. Multiple sclerosis, type 1
diabetes, rheumatoid arthritis, autoimmune disease of the
thyroid, and inﬂammatory bowel disease.
At the end of this paper, an example of the utility of
vitamin D in idiopathic thrombocytic purpura, another au-
toimmune disease, is discussed.
2. A Brief Overview of Vitamin D and Its
PotentialRole in AutoimmuneDisease
Vitamin D deﬁciency is common in latitudes far from the
equator [10, 11], and solar abstinence has been in vogue
for the past few decades for fear of inducing skin cancer.
Sun exposure (a minimal erythemal dose with full body
exposure) can rapidly produce 10,000 or more units of
vitamin D [12], and toxicity has not been ascribed to this
method of achieving normal vitamin D status. Vitamin D
used orally at 10,000IU a day for several months does not
cause toxicity [13]. Vitamin D is a secosteroid hormone2 Journal of Environmental and Public Health
Table 1: Agents that trigger autoimmune disease.
Infections Epstein-Barr’s virus, cytomegalovirus, parvovirus, enteropathogenic bacteria
Vaccine immunogens
Multiple sclerosis, Guillain-Barre’s syndrome, autism, rheumatoid arthritis,
reactive arthritis, systemic lupus erythematosus, diabetes, vasculitis,
dermatomyositis, polyarteritis nodosa
Adjuvants used to enhance immune response Lupus erythematosus, brain directed autoantibodies, arthritis, nephritis
Birth control, pregnancy Autoimmune thyroid disease
Smoking Rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis,
Graves’ hyperthyroidism, Crohn’s disease
Stress Type 1 diabetes, Grave’s disease
Adapted from [3, 4].
Table 2: Autoimmune diseases that are inhibited by 1,25(OH)2D
in animal studies [6].
Autoimmune encephalomyelitis
Collagen-induced arthritis
Inﬂammatory bowel disease
Type 1 diabetes
Systemic erythematosus
Thyroiditis
Lyme arthritis
Rheumatoid arthritis
Multiple sclerosis
Figure 1: Autoimmune disease causation triangle. Adapted from
[9]. Used with permission.
available in some foods and supplements or produced in the
skin from 7-dehydrocholesterol after exposure to ultraviolet
B light. The resulting previtamin D is then hydroxylated
in the liver to hydroxyvitamin D (25(OH)D) and further
hydroxylated in the kidney to 1,25-dihydroxyvitamin D
(1,25(OH)2D) which is the active hormone involved in
calcium absorption in the gut. Circulating 25(OH)D (which
is considered the measure of vitamin D adequacy) may
also be used as substrate in many cells to locally produce
(1,25(OH)2D), the active hormone, via the CYP27B1 (1α-
hydroxylase) enzyme and is inactivated by the CYP24A (24-
hydroxylase) enzyme [14]. The classical role of vitamin
D is to regulate calcium homeostasis [15]. Short latency
diseases, such as rickets and osteomalacia, can be cured with
25(OH)D levels >25nmol/L. In a long-latency disease, such
as osteoporosis, levels of 25(OH)D > 50nml/L have been
shown to reduce fractures.
In the last twenty years, the importance of vitamin D in
theroleofahormonehasbeenshowntoinﬂuencenumerous
other diseases including cancer by increasing apoptosis in
cancer cells and protecting DNA in normal cells [16]. Its
eﬀectontheimmunesystemandinfectionsisonlybeginning
to be understood, and much higher doses of vitamin D may
be needed to be eﬀective in combating viruses, bacteria, and
fungi[17].VitaminDisnowrecognizedtobecrucialinbeta-
defensin production in Crohn’s disease [18].
The role in regulating the immune system in regards to
self-toleranceandautoimmunitybeginswithanunderstand-
ing of the impact of vitamin D on our genes. Research is
showing that there are 2776 “binding sites” on the human
genome to which vitamin D attaches, with at least 229
genes associated with Crohn’s disease and type 1 diabetes
[19]. Many of the sites are concentrated around genes
linked to autoimmune conditions as described in this paper.
Beyond this, vitamin D suppresses autoimmune disease
pathology by regulating diﬀerentiation and activity of CD4+
T cells resulting in a more balanced T1/T2 response favoring
less development of self-reactive T cells and autoimmunity
[2].
3. Multiple Sclerosis
In regards to the host, it is known that only 30% of monozy-
gotictwinpairseventuallygetmultiplesclerosis(MS)leading
ustobelievethatexposuretooneormoreenvironmentalrisk
factorsisnecessaryforthedevelopmentofMS[20].Recently,
two large genomic studies have conﬁrmed the unambiguous
associations with the DRB1 and DQB alleles of the human
leukocyte antigen class II region and susceptibility to MS
[21].Journal of Environmental and Public Health 3
Multiple environmental factors may play a role in multi-
ple sclerosis. An example is the Epstein-Barr virus infections
[22]. The risk of developing multiple sclerosis following
infectious mono is increased signiﬁcantly for more than 30
years following infection [23]. Even after 10 years following
infection, the risk has been deﬁned as at least four-fold
[24]. Sunlight and vitamin D may be protective, and MS
demonstrates vitamin D sensitivity [25].
Evidence shows that MS correlates positively with higher
latitude, with latitudes >37.5 degrees from the equator
having signiﬁcantly higher rates of MS [26–29]. The time
of the ﬁrst exacerbation after disease onset shows seasonal
variation with 76% of exacerbations occurring in winter
[30]. However, in another study, the likelihood and intensity
of MS disease activity correlated positively with spring and
summer (March to August) along with increased tempera-
ture and UVR [31]. Relapses of MS have a biphasic pattern
with peaks in early spring when vitamin D levels are low and
late fall when levels are declining [32]. MS also correlates
positively with season of birth, with a signiﬁcantly higher
incidence of MS in those born in May, corresponding to
low vitamin D levels in the winter months prior to giving
birth [33]. As well, MS correlates inversely with altitude,
with higher elevation (>2000 Meters) receiving more intense
solar radiation having lower rates of MS [34]. Adiposity
has been associated with lower vitamin D levels [35, 36],
and a higher body mass index (BMI) has been associated
with higher incidence of MS in adolescent women but not
in adult women [37]. Multiple sclerosis correlates positively
with skin color where sun avoidance is more likely (fair skin
phenotype)[38].InNorway,theintakeofvitaminDincostal
communitiesisestimatedtobethreetimestheaverageintake
of those living inland and this is inversely associated with MS
[39].
There are only a limited number of trials currently avail-
able in humans. An American study of more than 187,000
women followed for 10–20 years showed promising results
with females taking at least 400IU of supplemental vitamin
D daily. The risk of developing MS was decreased by 40%
[40]. Vitamin D3 has been used safely in MS patients at
high doses from 28 to 280, 000IU per week. Mean levels
of 25(OH)D rose to a mean of 385nmol/L without causing
hypercalcemia after being given the highest dose. Disease
progression and activity were not aﬀected in this study, but
the number of gadolinium-enhancing lesions per patient
assessed by nuclear magnetic brain scan was signiﬁcantly
reduced [41]. The highest dose in this study was only used
for the last 6 weeks of the study, and longer-term use at
this dose may risk signiﬁcant toxicity in some patients. A
trial using high-dose vitamin D2 to achieve 25(OH)D levels
of 130–195nmol/L did not reduce MRI lesions in relapsing
remitting multiple sclerosis [42]. In a recently reported trial
using escalating doses up to 40,000IU of vitamin D3 for
28 weeks followed by 10,000IU daily for 12 weeks, there
were no signiﬁcant adverse events and there appeared to be
signiﬁcantly less progression of disability in the treatment
group [43].
4.Type1Diabetes
As with multiple sclerosis only about 34% of identical twins
w i l ld e v e l o pt y p e1d i a b e t e s[ 44]. Thus, exposure to other
environmental stimuli must play an important role.
In the past rubella infection has been implicated as an
inducer of type I diabetes. Several studies now indicate infec-
tion with enteroviruses seem to be linked to the induction
of islet cell destruction and development of autoantibodies
[45, 46]. Stress in the mother during pregnancy has been
associated with elevated islet autoantibodies in cord blood
[47].
The following is a summary of the evidence that type
1 diabetes is a vitamin D-sensitive disease. Type I diabetes
varies by latitude with higher incidence in latitudes further
from the equator (both north or south of the equator)
except where local weather may inﬂuence this [48]. A yearly
cyclical pattern (consistent over 20 years) of type 1 diabetes
in Newfoundland reveals a peak incidence in winter [49].
Greater exposure to erythemal UVB radiation is negatively
correlated with the incidence of type 1 diabetes [50]. The
birth months of March to June correlate with an increased
incidence of diabetes in Britain with prenatal exposure to
low vitamin D levels during the winter months [51]. The
average yearly temperature also correlates inversely with
the incidence of type 1 diabetes [52]. Higher BMI as well
as lower plasma levels of 25(OH)D correlate directly with
development of type 1 diabetes in young adults [53, 54].
Maternal vitamin D levels have been shown to correlate
inversely to the presence of islet autoantibodies in the oﬀ-
spring [55]. Supplementation of vitamin D in early child-
hood appears to reduce the chances of developing type 1
diabetes [56].
There is a large body of evidence showing that lack of
vitamin D early in life is linked to the development of type
1 diabetes. Vitamin D used at a dose of 2000IU in infants
has been shown to reduced the subsequent development
of type 1 diabetes over the next thirty years by 78 percent
[57] .T h eu s eo fc o dl i v e ro i li np r e g n a n c ya n dd u r i n g
the ﬁrst year of life has been shown to reduce the risk
of childhood onset type 1 diabetes. However, it was not
possible to determine if vitamin D, omega-3 fatty acids, or
the combination contributed to this result [58, 59]. The use
of400IUofvitaminDhasnotbeenshowntoreducediabetes
incidence [60]. In Finland the use of 2000IU of vitamin
D in children was recommended from 1964 to 1975 when
it was lowered to 1000IU of vitamin D supplementation
with a small increase in type 1 diabetes incidence following
this recommendation. A further reduction to the use of
400IU of vitamin D in 1992 correlates with a signiﬁcant
rise in the incidence of type 1 diabetes since then [61]. A
meta-analysis and systematic review on the use of vitamin
D supplementation in early childhood in type 1 diabetes
showed that the risk of developing type 1 diabetes was
signiﬁcantly reduced in infants with supplementation [56].
The pooled odds ratio was 0.71 (a CI of 0.60 to 0.84),
and there was evidence of a dose-response eﬀect showing
a lower risk of developing type 1 diabetes with the use of
higher amounts of vitamin D. In regards to sun exposure,4 Journal of Environmental and Public Health
theincidenceoftype1diabetesapproacheszeroinareaswith
high levels of UVB irradiance [48].
5. Rheumatoid Arthritis(RA)
The maximum genetic contribution indicated by studies on
monozygotic twins is about 15% when it comes to rheuma-
toid arthritis (RA) and systemic lupus erythematosus (SLE)
[62]. The HLA-DRB1gene represents the majordeterminant
of genetic predisposition to RA [63].
TheassociationofinfectionsandRAisstillbeingdebated
in the literature. There is some evidence that RA-like diseases
may result from the immunologic interaction between the
host and bacterial peptidoglycans. Several agents relative
to RA have been entertained such as heat shock proteins,
bacterial IgG FC-binding proteins and rheumatoid factors
[64]. Retroviruses and enteropathogenic bacteria continue
to be intensively discussed candidates [65]. IgM antibodies
to parvovirus B19 indicating recent infection correlate with
juvenileidiopathicarthritis[66].Certainlysmokinghasbeen
cited as being a major risk factor both in RA and SLE as well
as a risk factor for RF-positive and anti-citrulline antibody
titers [67]. The risk only diminishes slowly after several years
of cessation of smoking.
Increasing latitude in the northern hemisphere has been
shown to correlate with increased risk of RA providing some
support for a beneﬁcial role of UVR [68]. Patients with un-
differentiated connective tissue diseases have a seasonal var-
iance in 25(OH)D levels, being signiﬁcantly lower than
controls in corresponding seasons [69]. Seasonal variations
showed lower disease activity with higher 25(OH)D levels
[70]. It appears that rheumatoid arthritis does not have
association with month of birth [71]. Rheumatoid arthritis
activity is inversely related to 25(OH)D levels [72]. Rheuma-
toid arthritis severity is associated positively with BMI with a
high BMI having a greater risk of low 25(OH)D levels [73].
The incidence of arthritis in children is highest in Caucasian
versus East Indian, First Nations as well as African American
[74, 75]. The Iowa Women’s Health Study showed an inverse
association of vitamin D intake and rheumatoid arthritis
[76] There was a 34% reduction in the development of
rheumatoid arthritis with greater vitamin D intake. Women
using a multivitamin with 400IU of vitamin D reduced
their risk of developing RA by 40% [76]. An open-label
study using a high-dose vitamin D3 analogue resulted in
improvement of symptoms in RA in 89% of patients with
45% of patients entertaining a complete remission [77].
6. Autoimmune Diseaseof the Thyroid
Autoimmune disease of the thyroid (AITD) is very prevalent
with 5% of the population being aﬀected. This includes both
Hashimoto’s (HT) and Graves’ disease (GD) [5]. Several
susceptibility genes for AITD have been identiﬁed, and it has
been estimated that up to 80% may be attributable to genes
[78]. However, the concordance rates in monozygotic twins
is about 30–60%, while dizygotic twins is only 3–9%, and
up to 50% of siblings of patients with GD having thyroid
autoantibodies [79]. Thus, environmental factors contribute
signiﬁcantly to the expression of the disease.
Environmental factors are numerous and include iodine
excess and deﬁciency, selenium deﬁciency, oral contraceptive
use, parity, low birth weight, seasonal variation, allergy,
smoking, radiation, viral and bacterial infections, and so
forth [78]. Overall, data suggests that cumulative cigarette
consumption signiﬁcantly increases the risk of developing
AITD [80]. Hashimoto’s thyroiditis is associated with vita-
min D insuﬃciency with AITD patients having signiﬁcantly
lower levels than controls [81, 82]. In AITD 72% of patients
had 25(OH)D levels less than 25nmol/L compared to
30.6% in healthy individuals. In patients with Hashimoto’s
thyroiditis, 79% had levels less than 25nmol/L compared to
52% in normal controls.
The lowest incidence of AIDT disease was found in
July to October (when vitamin D levels are high), and the
highest incidence was in January to March when vitamin D
levels tend to be low in the northern hemisphere [83]. The
incidence of diagnosis of thyrotoxicosis is highest in May
just after the winter when vitamin D levels are beginning to
rise; however, this may also be a reﬂection of feeling hot
with increasing ambient temperatures [84]. There is no in-
formation on altitude or temperature. Vitamin D levels are
lower in AITD patients than in normal controls and sup-
plementation is recommended [82]. There are presently no
studiesusingvitaminDasaninterventioninAITD;however,
supplementation has been suggested.
7.Inﬂammatory BowelDisease
In regards to genetic predisposition, a national German
study has shown that concordance rates in monozygotic
twins are about 35% for Crohn’s disease (CD) and 16% for
ulcerative colitis (UC), showing that environmental factors
play a signiﬁcant role in inﬂammatory bowel disease (IBD)
[85].
An environmental trigger shown to increase the risk of
development of CD is smoking. Many other triggers have
been proposed such as infectious gastroenteritis, oral con-
traceptives, invasive E. coli, and antibiotics [86]. Vitamin D
insuﬃciency is associated with inﬂammatory bowel disease
[87, 88]. In another study 25(OH)D levels were lower in
those with severe disease activity and less sun exposure [89].
A study in France has shown that there is an increasing
incidence of UC with northern latitude [90]. Smaller studies
did not show any seasonal pattern for IBD, but a larger study
showed an increase incidence in those born in the ﬁrst half
of the year [91] while others show an increased incidence
of exacerbations in summer. There is no information on
altitude or temperature. Obesity is more common in Crohn’s
disease at the time of diagnosis [92]. Vitamin D deﬁciency
is very prevalent in IBD [93] and the eﬀects of low-dose
supplementation are poor [94]. A clinical trial using 1200IU
of vitamin D3 for 12 months resulted in a reduced risk of
relapse from 29% to 13%, although this did not quite reach
statistical signiﬁcance [95]. Other trials are currently under
way.Journal of Environmental and Public Health 5
AstrikingexampleinwhichvitaminDmadeasigniﬁcant
change in morbidity in another autoimmune disease follows.
8. A Case History andDiscussion of the
Beneﬁt of VitaminD in Idiopathic
Thrombocytopenic PurpurainanAdult
Idiopathic thrombocytopenic purpura (ITP) is an autoim-
mune disease in which most patients have antibodies to spe-
ciﬁc membrane glycoprotein’s on platelets. The incidence in
adultsisabout33/1,000,000[96]ofwhichabout10/1,000,000
become refractory. Spontaneous remission is uncommon in
adults. The 5-year mortality rate is signiﬁcantly elevated in
adults over the age of 60 (47.8%) versus those below 40 years
of age (2.2%), respectively. The most serious complication
is hemorrhage of which intracranial hemorrhage is the most
signiﬁcant.
Vitamin D has been shown to improve outcomes and
prevent some autoimmune diseases if taken early in life as
discussed previously in the paper.
Treatment of ITP usually includes medications such as
corticosteroids, splenectomy danazol, and various immune
suppressant therapies [97]. The use of vitamin D3 in ITP has
not been described in the literature.
This example describes a patient who had refractory ITP
whohasbeentreatedinthepastwithasplenectomy,danazol,
and prednisone rescue during intercurrent illness. A review
of the history of this case revealed a 48-year-old female
who was found to have a very low platelet count in 1998,
which remained persistent over time. After consultation with
a hematologist, the diagnosis of ITP was made. Her platelets
continuedtodropsoshehadasplenectomy,whichimproved
her platelet count, but it never achieved normal. Despite
the use of danazol, her platelet count never normalized. She
had frequent episodes of low platelets as low as 8×109 with
intercurrent illnesses such as colds or ﬂus. In 2006 she was
found to have an inadequate level of 25(OH)D of 65nmol/L.
Her platelet count at that time was 8×109 after a viral
illness. She was treated successfully with a tapering dose of
Prednisone. She was started on vitamin D3 2000IU daily
afterthisepisodeandduringthenexttwoyearswhileshewas
onthisdoseshedidnothaveanyﬂusorcoldsandherplatelet
count never fell below 44×109and was usually from 70 to
80×109. This was quite out of the normal for her since she
had at least one low episode a year. After being on this dose
for two years, a neighbor in her building where she resided
suggested that she was going to become toxic on this dose
and she stopped her vitamin D. About three months later,
she again had an upper respiratory infection (URI) and her
platelets dropped only to 50×109 and she was started on
prednisone with recovery of her platelets to 140×109.S h e
was seen after this, and it was recommended that she resume
her vitamin D3 at a higher dose of 4000IU daily. She was
feeling quite well, and her platelets remained above 70 and
continued to rise so she discontinued her danazol. Again, she
had no further episodes of ﬂu or colds for the next two years
and her platelets did not drop below 70. Her vitamin D level
on this dose was 88nmol/L after 4 months. She phoned one
daythatshewassickwithaURI,anditwassuggestedthatshe
take10,000IUofvitaminDfora3daysandhaveherplatelets
checked. She had her platelets checked after being on this
dose for two days, and they were in the normal range much
higher than they had been for years. The platelet count was
248×109. Her vitamin D level was 99nmol/L at this time.
She continues on the 4000IU vitamin D, and she continues
oﬀthedanazolandremainswell.Herlatestplateletcountwas
318×109.
This case presents a signiﬁcant response to vitamin D3
in ITP. As well, it demonstrates a recurrent failure with lack
of vitamin D and restoration of a normal platelet count
on a higher dosing of vitamin D3, which did not result in
toxicity. The vitamin D3 rescue with 10,000IU of vitamin D3
appeared to result in a similar response as that of prednisone
used in past treatments over the years. ITP has been shown
to have spontaneous remission in some people; however, it is
uncommon in older patients. Is it possible that restoration of
vitaminDlevelsresultsinsomeofthesecasesofspontaneous
resolution? At this time this is not known. Restoring vitamin
D to a level that is safe appears to be sensible supportive
therapy.
Restoration of adequate platelets has never been demon-
strated with repletion of inadequate vitamin D levels in the
literature. Certainly in this example, vitamin D3 restoring
reasonable platelet levels and reducing the number of
infections is most fascinating. The reduction in platelet levels
with removal of vitamin D3 with restoration of normal levels
with an increased dose of vitamin D3,a sw e l la sr e s c u ew i t h
higher levels of vitamin D3, is furthermore more intriguing.
More studies would be warranted to demonstrate the beneﬁt
of adequate 25(OH)D levels in ITP.
9. Discussion and Conclusion
This paper outlines a number of autoimmune diseases that
show vitamin D sensitivity as provided by supplementation,
UVR, or other factors. These factors have been summarized
in Table 3. At this time the research on the role of vitamin
D in autoimmune disease is not conclusive, and much of
the data comes from epidemiologic or case control studies.
However, the evidence is increasingly pointing towards a
signiﬁcant role of vitamin D in reducing the incidence and
burden of autoimmune diseases.
The link between various autoimmune diseases and
vitaminDinvariousecological,population, andcasecontrol
studies is summarized in Table 4. Interventional studies
when available have been cited throughout this paper.
Although not all linkages are positive in each disease, the
ones that have been studied the most, such as MS and
type 1 diabetes, are quite striking. Studies done in type 1
diabetes were done in infants, and supplementation during
the prenatal and ﬁrst year of life may result in a signiﬁcant
reduction of morbidity later in life. Vitamin D may very well
be a signiﬁcant factor in preventing the loss of tolerance to
self and resultant autoimmune disease.
Population studies have shown consistently in many
“northern” countries (i.e., Canada) that the majority of the6 Journal of Environmental and Public Health
Table 3: Autoimmunity and factors that relate to vitamin D-sensitive diseases.
Parameters relating to
vitamin D
Multiple
Sclerosis
Type 1
diabetes
Rheumatoid
arthritis
Autoimmune
disease of
thyroid
Inﬂammatory
bowel disease
Incidence seasonality + + + + −
Seasonality of birth + + − ++
Latitude + + + N/A +
Altitude + N/A N/A N/A N/A
Temperature + + N/A + N/A
BMI + + + N/A +
Race (skin tone) + + − N/A N/A
UV radiance + + + + +
Vitamin D intake + + + + +
Evidence from studies listed in the paper for positive correlation of vitamin D-sensitive parameters in each disease. +: positive correlation, −:n e g a t i v e
correlation, N/A: information lacking.
Table 4: Human studies in autoimmune disease.
Autoimmune disease Study design (N)R e s u l t s
Multiple sclerosis Prospective cohort studies NHS, NHS II
supplementation of vitamin D (N = 187,365) [40]
40% reduction in developing MS with
supplementation of 400IU vitamin D
Open label progressive supplementation of vitamin D
(N = 12) [41]
The number of gadolinium-enhancing
lesions was reduced
Randomized control using 1000IU versus 6000IU
daily of vitamin D2 for 6 months (N = 23) [42]
Vitamin D2 was not eﬀective in reducing
MRI lesions in RRMS
Open-label randomized controlled trial (N = 49) [43]
8% in the treatment group had worsening
disability versus 38% of patients in the
control group
Diabetes Birth cohort study (N = 12058) [57] Use of 2000IU had a reduced risk of
developing diabetes by 78%
Newly diagnosed diabetic children from 1980–2005
(N = 10737) [61]
Signiﬁcant increase in incidence noted
after reduction in vitamin D intake rec-
ommendation (decreased daily recom-
mendation from 1000IU to 400IU)
Meta-analysis of supplementation of vitamin D in
infants [56]
29% reduction in risk of developing type
1 diabetes
Rheumatoid arthritis Prospective cohort study dietary and supplement
vitamin D intake (N = 29,368) [76]
34% reduction in developing RA in the
supplement group >400IU vitamin D
Open-label trial using high-dose oral alphacalcidiol
therapy, (N = 19) [77]
Result in a positive eﬀect on disease
activity in 89% of patients
Autoimmune thyroid
disease None available to date
Crohn’s disease Randomized double-blind placebo-controlled study
(N = 94) [95]
1200IU of vitamin D3 reduced the num-
ber of relapses in the treatment group by
more than 50% during a 1yr study
population is vitamin D deﬁcient. Knowing that a large
proportion of the population do not have adequate levels of
vitaminD,itmaybeprudenttorestorelevelsto>100nmol/L
for optimum function of the immune system. 2000IU of
vitamin D3 has been shown to improve vitamin D status and
achieve these levels in about 80% of patients [98]. This may
decrease autoimmune disease incidence. Increasing vitamin
D intake would beneﬁt the general population with better
bonehealthandpreventionofcancerandinfectiousdiseases.
An estimate in the savings in healthcare expenditures with
restoration of adequate vitamin D is in the billions of dollars
[99, 100] These estimates include only a few of the many
autoimmune diseases that vitamin D may mitigate. Further
studies are warranted in addressing autoimmune disease and
vitamin D. These studies should use vitamin D3 since, as in
the above outlined studies, vitamin D2 was not eﬀective and
thelatestevidencesuggeststhatonlyvitaminD3,notvitamin
D2, improves mortality [101].Journal of Environmental and Public Health 7
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